Market Research Report
ASIA PACIFIC DRUG DISCOVERY MARKET FORECAST 2018-2026
|Published by||Inkwood Research||Product code||609207|
|Published||Content info||87 Pages
Delivery time: 1-2 business days
|ASIA PACIFIC DRUG DISCOVERY MARKET FORECAST 2018-2026|
|Published: March 2, 2018||Content info: 87 Pages||
The Asia Pacific drug discovery market t is predicted to exhibit a CAGR of 10.40%.
China is the most lucrative market for drug discovery in APAC. Over 80% of the Chinese pharmaceutical market is into generic drugs. That percentage is multiple times higher than a developed country like the U.S. Also, innovations in China are significantly improving. Over the past few years, the Indian pharmaceutical companies, too, have been attempting to re-orientate their efforts toward developing new innovative medicines. By exhibiting the highest CAGR between 2018-2026, the Australian drug discovery market is expected to attract major global market players. Compared to other APAC countries, the level of awareness amongst Australians regarding various health issues is much higher.
Bayer Ag, Sanofi, AstraZeneca Plc, Eli Lily, Pfizer Inc, Merck & Co. Inc, GlaxoSmithKline Llc, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd and Johnson and Johnson are some of the leading players in this market.